Antibody Discovery

Fusion Antibodies is a specialist contract research organisation (CRO) supporting antibody discovery and engineering services from antigen design through to validated lead selection. Our integrated platforms utilize hybridoma technology, rabbit monoclonal discovery, phage display antibody discovery, mammalian display, and AI-assisted antibody discovery to maximise epitope coverage, functional diversity, and developability of candidate antibodies.

We support biotech and pharmaceutical teams seeking an end-to-end antibody development partner for biologics discovery, lead optimisation, and preclinical drug discovery programmes.

Antibody discovery is the process of identifying and isolating antibodies that bind specifically to a biological target (antigen), typically for therapeutic, diagnostic, or research applications.

In therapeutic antibody discovery, the goal is to generate antibodies that are not only high-affinity binders but also:

• Functionally active against the target biology
• Structurally stable and manufacturable
• Suitable for downstream antibody engineering and development
• Compatible with humanisation and affinity maturation strategies

Modern antibody discovery integrates multiple technologies including antibody library design, antibody library screening, display systems, and immunisation-based methods to maximise success rates.

Antibody discovery programmes often fail or slow due to predictable technical bottlenecks in early biologics discovery:

• Suboptimal antigen design leading to weak or irrelevant immune responses
• Platform mismatch between discovery method and target biology (e.g. membrane proteins vs soluble antigens)
• Limited epitope diversity caused by immunodominance in animal systems
• Downstream engineering constraints such as humanization, affinity maturation, or antibody optimisation challenges
• Developability risks including aggregation, poor expression, or instability
• Unpredictable timelines from iterative screening or low-yield campaigns

These challenges directly impact progression into lead optimisation, antibody characterisation, and preclinical development.

Fusion Antibodies mitigate these risks through early-stage scientific design, differentiated discovery workflows, and integrated developability assessment.

Our antibody discovery process is designed to connect upstream biological insight with downstream therapeutic development.

We evaluate biological context, disease relevance, and therapeutic modality to define discovery strategy and epitope requirements.

We engineer optimised antigen constructs to improve immune response, display selection, and epitope presentation.

We select the most appropriate discovery route based on target class, risk profile, and downstream therapeutic format:

• Hybridoma antibody discovery
• Rabbit monoclonal antibody discovery
• Phage display antibody discovery
• Mammalian display service (OptiMAL®)
• AI antibody discovery (AI/ML-ab™)

We identify and validate antigen-specific binders using antibody library screening, functional assays, and binding characterisation.